Comments on: “Double your money … Guaranteed” Access Group

By: cancer researcher

cancer researcher — Tue, 14 Apr 2009 02:23:40 +0000

Given the “cost” of being a life member of the Gumshoe Irregulars, this reinforces my point. And I agree with the larger point, does this product add bottom-line value to one’s practice if you do the biopsy and pathology anyway?

By: skin

skin — Fri, 10 Apr 2009 20:00:09 +0000

“physicians are terribly frugal”
Hey, I may be frugal, but I recognize value: I’m a life member of the Gumshoe Irregulars. ;->

By: cancer researcher

cancer researcher — Fri, 10 Apr 2009 00:53:32 +0000

I’d go with the comments from the practicing dermatologist. First, the offer of $50 is not a sufficiently high enough “tease” to give the dermatologist a big enough piece of the action. Second, they get a take-to-the-bank pathology report when they do a biopsy, which they would do anyway after the machine gives a postive signal. So it becomes a redundancy. Moreover in current practice, if there is any suspicion, you do a biopsy. So the device doesn’t really interject a cost savings. Finally physicians are terribly frugal, and they may be happy if someone else springs for the $5000 upfront, but not the stand-alone pratitioner. However in the hospital setting, they just send it over to pathology and transfer the diagnostic risk to them. So in short, these folks will need a HUGE marketing budget, and will need to market it for quite a period of time. I was head of research for a biotech firm many eons ago and we had let’s say a vaguely related product, and in the end, they went belly up trying to overcome the marketing challenge. Thus I would say that this could be played as a market-news stock, riding it up with the hype, shorting it down as the reality of marketing sets in. Just don’t think you can make money from the fundamentals of a lucrative bottom line.

By: StockGumshoe

StockGumshoe — Thu, 09 Apr 2009 23:53:42 +0000

Thanks skin — always good to hear the details from someone in the biz.

It seems like one value of this kind of product (aside from being better than a non-dermatologist, which isn’t their market) might be in reducing unnecessary biopsies … but perhaps that’s too risky anyway, as it seems likely that erring on the side of caution would still be the likely course. Just curious, I clearly have no expertise on the sector or the business, and I don’t know how the study was designed that had the MelaFind “beating” the dermatologists.

By: Dave

Dave — Thu, 09 Apr 2009 22:47:08 +0000

I’ll pay you $1,000. What do you make of this?

Dear Growth Stock Wire Reader,

Are you willing to quit stocks for the next 30 days?

If so – a $1000 check delivered via Federal Express could be yours in 30 days.

In return, we want you to simply stop buying stocks. Tell your broker to take a vacation. Whatever you do, just DO NOT buy any shares of a public company. Take this to heart, and the money’s yours.

Details below.

Sincerely,

Brian Hunt
Editor in Chief, Growth Stock Wire